AVTE

Aerovate Therapeutics, Inc.

18.66 USD
-0.97 (-4.94%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Aerovate Therapeutics, Inc. stock is up 1.69% since 30 days ago. The next earnings date is Mar 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 February’s closed higher than January.

About Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc. focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company is advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.